Drug Metabolism and Personalized Therapy

Aims & Scope

Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services.

It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion.

Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.

View Aims & Scope

---

Metrics & Ranking

Journal Rank

Year	Value
2024	17693

Journal Citation Indicator

Year	Value
2024	135

SJR (SCImago Journal Rank)

Year	Value
2024	0.271

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	40

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Influence of <i>CYP3A4</i> and <i>CYP3A5</i> polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients

  Citation: 36

  Authors: Erika Y., Claudia R., Fabiana D.V., Alice C., Antony B., Rosario D.C., Helio, Jose O.

• Metabolism and mechanisms of action of hyaluronan in human biology

  Citation: 33

  Authors: Reenu Anne, Narendranath, Prasanth S.

• An update on <i>HLA</i> alleles associated with adverse drug reactions

  Citation: 31

  Authors: Ingrid, Adrián, Marisol

• Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins

  Citation: 27

  Authors: Annett, Birk, Jörg, Gian

• Genetic polymorphisms of cytochrome P450 enzymes: <i>CYP2C9</i>, <i>CYP2C19</i>, <i>CYP2D6</i>, <i>CYP3A4</i>, and <i>CYP3A5</i> in the Croatian population

  Citation: 26

  Authors: Lana, Tamara, Nikica, Mila, Petar, Nada

• Pharmacogenetics of drug-metabolizing enzymes in US Hispanics

  Citation: 25

  Authors: Karla, Jorge, Carmen L., Gualberto

• Enhanced oral bioavailability of metoprolol with gallic acid and ellagic acid in male Wistar rats: involvement of CYP2D6 inhibition

  Citation: 24

  Authors: Bhargavi Latha, Prasad

• Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects

  Citation: 23

  Authors: Richat, Joseph, Daryl

• Pharmacogenetics and pharmacogenomics as tools in cancer therapy

  Citation: 23

  Authors: Ana E., Eva, Jesus M., Miguel, Antonio, Carlos López, Salvador Martín, David, Miquel

• Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations

  Citation: 20

  Authors: Ann K.

---